1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. ONESOURCE SPECIALTY PHARMA LTD.
OneSource Specialty Pharma Ltd.
NSE: ONESOURCE | BSE: 544292

OneSource Specialty Pharma Live Share Price Today, Share Analysis and Chart

Momentum Trap
aboutOneSource Specialty Pharma Ltd. (ONESOURCE) is a multimodal pure-play specialty pharmaceutical Contract Development and Manufacturing Organisation (CDMO). The company provides end-to-end services across advanced technology platforms and therapeutic m... Read More
US FDA InspectionsANDA Approvals
Ask AI about OneSource Specialty Pharma
1558.20-4.80(-0.31%)

47.42% Gain from 52W Low

347.9K
NSE+BSE Volume

High vol.+gain this week

NSE 02 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
50.2 / 100
Momentum TrapThese stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise cautionView SimilarEmbed DVM
Analyst Price Target
-

14

S

16

W

6

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Low rank

7Positive15Negative

31.8%Pass in checklist

045
55
100

Check P/E Buy Sell Zone

This stock has negative PE

OneSource Specialty Pharma Stock Price Analysis

Day Price Range

-0.3% 1 Day return
1558.2 (LTP)
1,542.21,601.5
LowHigh

Week Price Range

16.8% 1 Week return
1558.2 (LTP)
1,326.11,642.9
LowHigh

Month Price Range

3.3% 1 Month return
1558.2 (LTP)
1,320.61,642.9
LowHigh

52 Week Price Range

-16.0% 1 Year return
1558.2 (LTP)
1,0571,925
LowHigh
View full Price History/Seasonality

OneSource Specialty Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

OneSource Specialty Pharma's Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

CURRENT EPS
-6.4
AVG. ESTIMATE
44.2
LOW ESTIMATE
43.8
HIGH ESTIMATE
44.5
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 785.6% in FY27

Consensus Recommendation

4 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 4 analysts for OneSource Specialty Pharma is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

OneSource Specialty Pharma Technical Analysis

OneSource Specialty Pharma EMA & SMA

Bullish+6
7 bullish, 1 bearish
Bullish7
Bearish1
5 Day1541.5
10 Day1508.4
12 Day1502.1
20 Day1495.8
26 Day1499.0
50 Day1521.5
100 Day1555.0
200 Day1585.7

OneSource Specialty Pharma Delivery And Volume

Daily Avg. Delivery Volume %
02 Nov, 202649.4%
Week27.4%
Month33.0%

OneSource Specialty Pharma Active Candlesticks

Long Legged Doji Uptrend Rickshaw Man Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

OneSource Specialty Pharma Resistance and Support

1567.30
Pivot
First Resistance1592.4
Second Resistance1626.6
Third Resistance1651.7
First Support1533.1
Second Support1508
Third Support1473.8
Day RSI57.5
Day MACD3.1
Day MFI79
Day MACD Signal Line-19.2

OneSource Specialty Pharma Beta

1 Month0.4
1 Year-0.2
3 Month0.3
3 Year-

OneSource Specialty Pharma Price Change Analysis

↑3.3%
Over 1 Month
LowHigh
1320.61642.9
↓-3.8%
Over 3 Months
LowHigh
1320.61657.5
↓-10.4%
Over 6 Months
LowHigh
1320.61917.8
↓-16.0%
Over 1 Year
LowHigh
10571925
All Technicals →

OneSource Specialty Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Tenshi Pharmaceuticals Private LimitedPromoter21,089,71418.4 %
Route One Offshore Master Fund L.P.Fii2,663,3102.3 %
Authum Investment And Infrastructure LimitedPublic5,681,8445.0 %
Motilal Oswal Mutual FundDii8,049,1397.0 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

OneSource Specialty Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONEBulkSell21 Apr 202615301,057,902NSE
AUTHUM INVESTMENT & INFRASTRUCTURE LIMITEDBulkSell21 Apr 20261530.09950,000NSE
AUTHUM INVESTMENT & INFRASTRUCTURE LIMITEDBulkPurchase21 Apr 20261556.69172,668NSE
FIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH FUNDBulkPurchase21 Apr 202615302,017,662NSE
AMANSA HOLDING PRIVATE LTD.BlockSell17 Nov 20251735200,000NSE
KARUNA BUSINESS SOLUTIONS LLPBlockPurchase17 Nov 20251735200,000NSE
MEDELLA HOLDINGS PTE. LTD.BulkSell15 May 20251568.04884,210BSE
MEDELLA HOLDINGS PTE. LTD.BulkSell31 Jan 20251548.541,941,747NSE
TENSHI PHARMACEUTICALS PRIVATE LIMITEDBulkSell31 Jan 20251545.031,941,747NSE
MEDELLA HOLDINGS PTE. LTD.BulkSell31 Jan 20251552.901,941,748NSE
All deals
All insider trades

OneSource Specialty Pharma Corporate Actions

OneSource Specialty Pharma Board Meetings

OneSource Specialty Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
127 Oct 2026
Quarterly Results-
224 Jul 2026
Quarterly Results-
313 May 2026
Audited Results-
423 Jan 2026
Quarterly Results-
511 Nov 2025
Quarterly Results-
All Corporate Actions

OneSource Specialty Pharma Research Reports

OneSource Specialty Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
105 Sep 2026ICICI Securities Limited24001537.8Buy56.07%1.33%pdf
225 Jul 2026ICICI Securities Limited24001653.9Buy45.11%-5.79%pdf
312 Nov 2025ICICI Securities Limited24751726Buy43.4%-9.72%pdf
All Reports of OneSource

OneSource Specialty Pharma Corporate Filings

OneSource Specialty Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its Sterile Product Division (SPD) Facility in Bengaluru.
PDF
28 Oct 2026
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation about publication of newspaper advertisement - Extract of unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2026.
PDF
27 Oct 2026
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of the Audio recording of the earnings call pertaining to the unaudited financial results for the quarter and half year ended September 30, 2026
PDF
27 Oct 2026
Q2FY27 Quarterly Result Announced for OneSource Specialty Pharma Ltd.
Pharmaceuticals company OneSource Specialty Pharma announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations stood at Rs 5,162.42 million for Q2FY27, indicating a QoQ growth of 14.97% from Rs 4,490.23 million in Q1FY27 and a YoY expansion of 37.38% from Rs 3,757.63 million in Q2FY26. For H1FY27, consolidated revenue from operations reached Rs 9,652.65 million, growing by 37.30% YoY compared to Rs 7,030.33 million in H1FY26. Total income stood at Rs 4,528.25 million for Q2FY27, experiencing a QoQ reduction of 12.45% from Rs 5,171.96 million in Q1FY27, but achieving a YoY growth of 19.54% from Rs 3,787.99 million in Q2FY26. For H1FY27, total income reached Rs 9,700.21 million, posting a 36.37% YoY increase from Rs 7,113.37 million in H1FY26. Profit before tax (PBT) stood at Rs 202.94 million for Q2FY27, falling by 61.61% QoQ from Rs 528.65 million in Q1FY27, but climbing by 253.49% YoY from Rs 57.41 million in Q2FY26. For H1FY27, consolidated PBT reached Rs 731.59 million, expanding significantly by 5,351.49% YoY from Rs 13.42 million in H1FY26. Profit after tax (PAT) reached Rs 249.97 million for Q2FY27, showing a QoQ drop of 56.52% from Rs 574.84 million in Q1FY27, but increasing by 138.41% YoY from Rs 104.85 million in Q2FY26. For H1FY27, consolidated PAT reached Rs 824.81 million, scaling up by 700.86% YoY from Rs 102.99 million in H1FY26. Earnings per share (EPS) basic stood at Rs 2.18 for Q2FY27, lower by 56.49% QoQ from Rs 5.01 in Q1FY27, but up 136.96% YoY from Rs 0.92 in Q2FY26. For H1FY27, basic EPS was Rs 7.19, reflecting a 698.89% YoY growth from Rs 0.90 in H1FY26. Standalone Financial Highlights: Revenue from operations stood at Rs 5,144.96 million for Q2FY27, representing a QoQ growth of 15.24% from Rs 4,464.71 million in Q1FY27 and a YoY expansion of 37.13% from Rs 3,751.87 million in Q2FY26. For H1FY27, standalone revenue from operations was Rs 9,609.67 million, demonstrating a 38.03% YoY increase from Rs 6,961.99 million in H1FY26. Total income stood at Rs 5,154.19 million for Q2FY27, higher by 14.47% QoQ from Rs 4,502.58 million in Q1FY27 and up 36.27% YoY from Rs 3,782.23 million in Q2FY26. For H1FY27, standalone total income reached Rs 9,656.77 million, marking a YoY growth of 37.07% against Rs 7,044.90 million in H1FY26. Profit before tax (PBT) stood at Rs 75.22 million for Q2FY27, reduced by 85.31% QoQ from Rs 512.25 million in Q1FY27 and down 79.73% YoY from Rs 371.01 million in Q2FY26. For H1FY27, standalone PBT was Rs 1,141.67 million, showing a YoY growth of 84.39% from Rs 619.16 million in H1FY26. Profit after tax (PAT) was recorded at Rs 75.22 million for Q2FY27, lower by 85.31% QoQ from Rs 512.25 million in Q1FY27 and down 79.73% YoY from Rs 371.01 million in Q2FY26. For H1FY27, standalone PAT reached Rs 1,141.67 million, a YoY acceleration of 84.39% from Rs 619.16 million in H1FY26. Earnings per share (EPS) basic stood at Rs 7.52 for Q2FY27, growing by 68.23% QoQ from Rs 4.47 in Q1FY27 and increasing by 132.10% YoY from Rs 3.24 in Q2FY26. For H1FY27, standalone basic EPS was Rs 11.98, accelerating by 121.44% YoY from Rs 5.41 in H1FY26. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: “Q2 delivered strong sequential growth, led by new DDC capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commercial volumes. Biologics momentum remained strong, with yet another US biotech onboarded during the quarter. With additional capacity and partnerships, we are well set for the next phase of growth.” Result PDF
PDF
27 Oct 2026
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
OneSource announces strong Q2FY27, results revenue up 37% YoY and EBITDA up 53% YoY
PDF
VIEW ALL

OneSource Specialty Pharma DocumentsAsk MarketMind AI

OneSource Specialty Pharma Earnings Call

OneSource Specialty Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
19 May 2026Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
13 May 2026Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationLink
13 May 2026OneSource Specialty Pharma Results Earnings Call for Q4FY26 & Full YearAudioVideo
18 Nov 2025Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
12 Nov 2025OneSource Specialty Pharma Results Earnings Call for Q2FY26AudioVideo
view all

OneSource Specialty Pharma Annual Reports

OneSource Specialty Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link

OneSource Specialty Pharma Credit Ratings

OneSource Specialty Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
16 Aug 2026india ratingsIndia Ratings Upgrades Onesource Specialty Pharma’s Bank Loan Facilities to ‘IND A’/Positive; Rates Additional LimitsLink
04 Mar 2026care ratingsOneSource Specialty Pharma LimitedLink
06 Oct 2025india ratingsConsolidation of Global CDMO Operations through Multi-Entity Merger Credit Neutral for OneSource Specialty PharmaLink
02 Jun 2025india ratingsIndia Ratings Assigns Onesource Specialty Pharma’s Bank Facilities ‘IND A-’; Outlook PositiveLink
19 Feb 2025care ratingsOneSource Specialty Pharma LimitedLink

OneSource Specialty Pharma Investor Presentations

OneSource Specialty Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
13 May 2026Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
12 Nov 2025Onesource Specialty Pharma Ltd - 544292 - Investor PresentationLink
26 Sep 2025Onesource Specialty Pharma Ltd - 544292 - Investor PresentationLink

OneSource Specialty Pharma - Company Profile

OneSource Specialty Pharma Management Structure

OneSource Specialty Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Neeraj SharmaExecutive Director,Managing Director,Chief Executive Officer669.3Mar 25
Trisha ACompany Secretary,Compliance Officer-Mar 25
Mr. Anurag BhaganiaChief Financial Officer-Mar 25
Mr. Biju MathewChief Operating Officer,Head(Operations)-Mar 25
Mr. Jeffrey WongChief Business Officer-Mar 25
Mr. Bernhard ThurnbauerChief Quality Officer-Mar 25
Mr. Prateek GuptaSenior Vice President,Head(Technical & Development)-Mar 25
Mr. Ravi KumarHead(Corporate Strategy,Operational Excellence)-Mar 25

OneSource Specialty Pharma Board of Directors

OneSource Specialty Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Neeraj SharmaManaging Director & CEO669.3Mar 25
Rashmi Harshadrai BarbhaiyaIndependent Non Exe. Director10Mar 25
Bharat ShahNon Executive Director7Mar 25
Vijay Paul KarwalIndependent Non Exe. Director-Mar 25
Trisha ACompany Sec. & Compli. Officer-Mar 25
Colin Michael BondIndependent Non Exe. Director-Mar 25
Claudio AlbrechtNon Executive Director-Mar 25
Debarati SenIndependent Non Exe. Director-Mar 25
Arun KumarChairman & Non Executive Dir.-Mar 25
Website: www.onesourcecdmo.com

About the company - Business Profile

OneSource Specialty Pharma Ltd. (ONESOURCE) is a multimodal pure-play specialty pharmaceutical Contract Development and Manufacturing Organisation (CDMO). The company provides end-to-end services across advanced technology platforms and therapeutic modalities, specifically focusing on complex areas such as biologics, drug-device combinations, sterile injectables, and oral technologies. Formed through the consolidation of the softgel business of Strides Pharma Science, the sterile injectables business of SteriScience, and the biopharma business of Stelis Biopharma, OneSource occupies a specialized niche in the global CDMO landscape.

Key Points

  • Key Facts: OneSource Specialty Pharma Ltd., formerly known as Stelis Biopharma Limited, is headquartered in Bengaluru, India. It was formed following a Scheme of Arrangement effective April 1, 2024, and made its market debut on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on January 24, 2025.
  • Operations and Resources: The company operates five manufacturing facilities approved by major global regulatory agencies including the USFDA, ANVISA, EMA, and TGA. These assets include:
    • An integrated Drug Substance-Drug Product (DS-DP) site for microbial and mammalian biologics.
    • A dedicated 550,000 sq. ft. space for process development and drug substance manufacturing.
    • Specialized facilities for sterile injectables, penicillin fill-finish, and soft gelatin capsules.
  • Ownership and Privatization: The company was created by merging businesses from Strides Pharma Science and SteriScience (a promoter group company). In October 2024, it received equity commitments of ₹8,010 million (USD 95 million) from investors at a pre-money valuation of USD 1.65 billion.
  • Market and Significance: OneSource serves global pharmaceutical and biotech partners, including four of the top five global generic companies. It is a significant supplier of Penicillin to the US market and handles over 20 device platforms for drug-device combinations.
  • Sustainability and Innovation: The company released its inaugural Integrated Report for FY25. It tracks ESG performance through an EcoVadis rating, which improved from 30 to 44 within the first year of review.

Business Model and Financials

The company’s business model is built on a "multimodality" platform, allowing it to offer services across the entire drug lifecycle from development to commercial manufacturing. It excels in handling complex drug-device combinations (DDC) and high-growth segments like GLP-1 products.

  • Revenue and Growth: For FY24 (Proforma), the company reported revenue of US$ 21.5 million, representing a 4.4x growth over the previous year. It achieved positive EBITDA for the first time in Q4 FY24 (adjusted for one-time expenses).
  • Financial Outlook (FY28 Target):
    • Revenue: Targeted at US$ 400 million (organic) or US$ 500+ million (including proposed acquisitions).
    • EBITDA Margin: Steady-state target of ~40%.
    • Revenue CAGR (FY25-28): Expected to exceed 30%.
    • Return on Capital Employed (ROCE): Targeted at >50%.
  • Revenue Breakdown: While specific geographical percentage splits were not detailed in the snippets, the company primary focuses on the US market (where it is a top 5 Penicillin supplier) and global generic leaders.
  • Employee Metrics: OneSource employs over 1,400 personnel, including a team of more than 200 scientists and techno-commercial leaders.
  • Strategic Initiatives: The company is executing a ~US$ 100 million CAPEX plan for capacity expansion, with 65% already committed. Key projects include accelerating Phase 2 of capacity expansion to be operational a year ahead of schedule and upgrading an injectables site to add niche pre-filled syringe (PFS) capabilities.

References

  1. Annual Report May 2025
  2. Investor Presentation Nov 2025
  3. Earnings Transcript Nov 2025
  4. Annual Report May 2024

OneSource Specialty Pharma FAQ

OneSource Specialty Pharma today is trading in the red, down by 0.31% at ₹1,558.2.
OneSource Specialty Pharma is currently trading down 0.31% on an intraday basis. In the past week the stock rose 16.8%. Stock has been down 3.8% in the past quarter and fell 15.96% in the past year. You can view this in the share price history/seasonality section.
OneSource Specialty Pharma is listed on NSE with the ticker ONESOURCE and on BSE as 544292. It's currently trading on NSE at a share price of ₹1,558.2 and on BSE with a share price of ₹1,559.5.
The market cap of OneSource Specialty Pharma is ₹17,868.47 Cr. as of Nov 02, 2026.
OneSource Specialty Pharma has never announced any dividend since the time of its listing on the BSE/NSE exchanges.
OneSource Specialty Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
OneSource Specialty Pharma reported ₹517.2 Cr. in revenue, ₹57.48 Cr. in net profit, and ₹162.48 Cr. in EBITD as of Oct 27, 2026 for Q2 FY26-27.
According to the predictions of 4 analysts, the share price prediction for OneSource Specialty Pharma is ₹2,078.25 with an upside of 33%.
The PE ratio of OneSource Specialty Pharma is -11022.92 as of Nov 02, 2026.
The PB ratio of OneSource Specialty Pharma is 3.05 as of Nov 02, 2026.
You can view the latest analyst reports on the OneSource Specialty Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×